Results 311 to 320 of about 146,874 (392)

Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials [PDF]

, 2017
et al,, Mutch, David G
core   +1 more source

Clinical Application of In‐House Comprehensive Genomic Profiling for Thoracic Cancer: Insights From a Japanese Hospital

Cancer Science, Volume 116, Issue 10, Page 2819-2830, October 2025.
We clarified the utility and challenges of in‐house comprehensive genomic profiling (CGP) testing in lung cancer care. ABSTRACT Comprehensive genomic profiling (CGP) is useful for optimizing targeted therapy and immunotherapy strategies for thoracic malignancies. This study aimed to evaluate the clinical utility and diagnostic complementarity of the in‐
Hatsuyo Takaoka, Hideki Terai, Kohei Nakamura, Takaaki Mizuno, Ryutaro Kawano, Katsura Emoto, Yutaka Kurebayashi, Nao Takada, Kenta Hamabe, Kazuhito Horie, Akihiko Ogata, Katsuhito Kinoshita, Lisa Shigematsu, Fumimaro Ito, Masahiko Okada, Takahiro Fukushima, Shigenari Nukaga, Testuo Tani, Keiko Ohgino, Kaoru Kaseda, Shinnosuke Ikemura, Hiroyuki Yasuda, Keisuke Asakura, Hajime Okita, Hiroshi Nishihara, Koichi Fukunaga   +25 more
wiley   +1 more source

Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2–Overexpressing Metastatic Breast Cancer

, 2006
Nicholas J. Robert, Brian Leyland‐Jones, Lina Asmar, Robert J. Belt, D. Ilegbodu, David Loesch, Robert N. Raju, Elizabeth Valentine, Robert M. Sayre, Melody Cobleigh, Kathy S. Albain, Cecelia McCullough, Lea Fuchs, Dennis J. Slamon   +13 more
openalex   +1 more source

Characterisation of mAb104 Antibody-Drug Conjugates Targeting a Tumour-Selective HER2 Epitope. [PDF]

Cancers (Basel)
Parakh S, Huynh N, Osellame LD, Cao DD, Rigopoulos A, Gloria B, Guo NY, Scott FE, Liu Z, Gan HK, Scott AM.   +10 more
europepmc   +1 more source

Trends in and Determinants of Approval Lag for Anticancer Drugs in Japan and the US: Role of Multi‐Regional Trials and Concurrent Approvals

Clinical and Translational Science, Volume 18, Issue 10, October 2025.
ABSTRACT Timely access to treatment for cancer patients requires the accelerated approval of new anticancer therapies. However, the lengthy pharmaceutical approval process in Japan has contributed to what is known as “drug lag.” Although recent efforts to promote international multi‐regional clinical trials (MRCTs) involving Japan and to advance ...
Hitoshi Kanno, Kotone Matsuyama
wiley   +1 more source

Additions of trastuzumab to preoperative chemotherapy or chemoimmunotherapy for patients with potentially resectable stage III to IV_B HER2-positive gastric cancer. [PDF]

Front Immunol
Zhang X, Tian Y, Wang H, Song S, Chen Y, Liu N, Zhang C, Huang X, Jiang H, Hou H.   +9 more
europepmc   +1 more source

Recent Advances and Future Directions in Bladder Preservation Therapy for Muscle‐Invasive Bladder Cancer

International Journal of Urology, Volume 32, Issue 10, Page 1334-1341, October 2025.
ABSTRACT Bladder preservation therapy has emerged as an essential alternative to radical cystectomy for muscle‐invasive bladder cancer, particularly in elderly or frail patients. Trimodal therapy, combining maximal transurethral resection of bladder tumors, chemotherapy, and radiotherapy, has shown comparable oncological outcomes to radical cystectomy ...
Tomokazu Kimura, Satoshi Inoue, Tomoyasu Sano, Kenji Zennami, Shusuke Akamatsu   +4 more
wiley   +1 more source

Real-world efficacy and safety of inetetamab-based therapy in HER2-positive metastatic breast cancer patients with prior exposure to trastuzumab. [PDF]

Front Oncol
Duan Y, Sun T, Chen Z, Ouyang Q, Li K, Yan M, Lv Z, Li Z, Man L, Luo X, Dong Y, Jing M, Wang Y, Guo X, Xu J, Li X, Jiang C, E Y, Jiang L, Cao H, Jia Y, Wu J, Li H, Zhang L, Jiang Y, Gao Z, Dong F.   +26 more
europepmc   +1 more source

Transforming treatment paradigms: Focus on personalized medicine for high‐grade serous ovarian cancer

CA: A Cancer Journal for Clinicians, Volume 75, Issue 5, Page 436-460, September/October 2025.
Abstract High‐grade serous ovarian cancer (HGSOC) is the most common and aggressive subtype of ovarian cancer, accounting for approximately 70% of all ovarian cancer cases and contributing significantly to the high mortality rates associated with this disease.
Pawel Kordowitzki, Britta Lange, Kevin M. Elias, Marcia C. Haigis, Sylvia Mechsner, Ioana Elena Braicu, Jalid Sehouli   +6 more
wiley   +1 more source

Trastuzumab: Is the new evidence revolutionary?

, 2006
Anusheel Munshi, Pritanjali Singh, Rakesh Jalali   +2 more
openalex   +1 more source